Iktar informazzjoni ― Malti

Acanthosis nigricans hija manifestazzjoni tal-ġilda ta’ kundizzjoni sottostanti. Spiss jidher fil-ġnub tal-ġilda bħall-għonq, l-arpits, u l-groin, qishom irqajja skuri bellusin bi trufijiet mhux ċari. Din il-kundizzjoni hija ġeneralment marbuta mad-dijabete u r-reżistenza għall-insulina, iżda f’każijiet rari, tista’ tindika kanċer ġewwa l-ġisem. Jista 'wkoll jidher minħabba kwistjonijiet ta' ormoni jew billi tieħu mediċini speċifiċi bħal sterojdi u pilloli għall-kontroll tat-twelid.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.

Acanthosis nigricans (AN) hija kundizzjoni komuni tal-ġilda marbuta ma 'diversi kwistjonijiet ta' saħħa bħal reżistenza għall-insulina, dijabete, obeżità, ċerti kanċers, problemi ormonali, u reazzjonijiet għal mediċini. It-trattament tal-AN jiffoka fuq l-indirizzar tal-problemi tas-saħħa sottostanti. Inizjalment, it-tobba jiċċekkjaw għal sinjali ta 'sindromu ta' reżistenza għall-insulina, li jinkludi obeżità, kolesterol għoli, pressjoni tad-demm għolja, u dijabete tat-tip 2. It-tobba ħafna drabi jippreskrivu topical retinoids bħala l-ewwel għażla ta 'trattament, li tista' tgħin fit-tħaxxin tal-ġilda. Madankollu, jistgħu ma jindirizzawx bis-sħiħ id-dlam tal-ġilda. Għażliet oħra ta 'trattament (salicylic acid, podophyllin, urea, calcipotriol) jeħtieġu wkoll applikazzjoni frekwenti.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.